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SUMMARY – The aim of this study was to analyze risk factors present in schizophrenic patients 
with depressive symptomatology. The sample comprised of 76 respondents diagnosed with schizo-
phrenia. In the study, we used the Positive and Negative Syndrome Scale (PANSS) and Calgary De-
pression Scale for Schizophrenia. The prevalence of depression was estimated to be 30%. The mean 
scores on the negative subscale of the PANSS were significantly higher in patients with schizophrenia 
and depression compared to control group (U=3.64, p=0.00), and so were those on the General Psy-
chopathology Scale (U=4.91, p=0.00). Socio-demographic factors were identified as important factors 
(p<0.05). Personal and environmental factors such as loneliness, immediate social environment, social 
support and isolation were statistically significantly different between the groups (p<0.05). There was 
a correlation of poor compliance with psycho-pharmacotherapy, increased number of hospitalizations 
and shorter remission period with the severity of clinical presentation (p<0.05). Since the presence of 
these factors is associated with depression in schizophrenia, their early detection in clinical practice is 
vital to ensure timely prevention of the development of depressive symptomatology.
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Introduction
Schizophrenia is a complex mental disorder with a 
variable phenotypic expression of symptoms in the 
form of impaired mental capacity, communication dif-
ficulties, affective response, difficulties in perceptions 
of reality and relationship with others, avolition and 
urges. Depressive symptoms are common in people 
with schizophrenia, but often confusing or neglected 
by clinicians1.
The prevalence of depressive disorder in schizo-
phrenia has been reported to be around 40%2, with an 
incidence varying from 13% to 60% depending on the 
stage of illness and the person’s current medical condi-
tion3,4. A vast majority of patients with schizophrenia 
experience one or more depressive episodes during the 
early stage of the illness, which makes it difficult to 
distinguish between schizophrenia and schizoaffective 
disorders. The presence of depression symptoms may 
be associated with a number of psychological factors 
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such as stress, sense of insecurity, hopelessness, social 
exclusion, and therefore it can be manifested at any 
stage during the illness. In addition to depressive 
symptoms, recurrent depressive episodes adversely af-
fect treatment outcomes in schizophrenia4, as well as 
the quality of life in these patients5,6. Furthermore, the 
relationship has been identified between the presence 
of depression and subsequent poor mental function-
ing, abuse of psychoactive substances, increased risk of 
psychotic relapse, and difficulty in establishing appro-
priate relationships in family environment7-9.
There is a high prevalence of suicide in patients 
with schizophrenia, most often linked to the presence 
of depression10-12. It has been estimated that in patients 
with schizophrenia, the number of attempted suicides 
ranges between two and five, whereas 10% of patients 
will take their own lives eventually13-15.
Diagnosing depression in schizophrenia may be 
difficult due to the problems of differentiating the 
symptoms of mood disorders from the presence of 
negative symptoms of schizophrenia. Factors associ-
ated with the manifestation of this mood and the ap-
pearance of depressive episodes can be the result of 
secondary negative symptoms such as avolition due to 
the insight into the illness and their own mental health 
condition, sense of shame, and self-distrust. Since the 
symptoms can manifest themselves in a similar way, in 
addition to commonly used assessment of cognitive 
functioning, hallucinations, anhedonia and affective 
gain, it is also of importance for appropriate diagnosis 
to assess the patient’s subjective responses to his/her 
mood, affective gain, speculation about future pros-
pects, the patient’s subjective mood responses, and the 
like. Recent research indicates that age, duration of ill-
ness, education degree, community life, physical health 
and quality of life affect the possible consequences of 
illness and the need for treatment16,17.
The Calgary Depression Scale for Schizophrenia 
(CDSS)18 can be used to measure the presence of clin-
ically significant depressive symptoms; therefore, the 
aim of this study was to analyze the risk factors present 
in schizophrenic patients with depressive symptom-
atology.
Patients and Methods
The survey included 76 subjects, 44 (57%) male and 
32 (43%) female, mean age 38.7 years (SD=9.14). All 
subjects had been diagnosed with F20 according to the 
International Classification of Diseases and Related 
Health Problems (ICD-10)19. They were currently re-
ceiving risperidone (Risperdal Consta), a long-acting 
injectable antipsychotic, and fulfilled the remission cri-
teria. The mean disease duration was 12 years (SD=3.48). 
Study subjects were divided into two groups according 
to the results obtained on CDSS, i.e. respondents with 
depressive symptomatology and control group of re-
spondents without depressive symptomatology.
The inclusion criteria for participants in the re-
search required that respondents were aged 18-60 and 
signed the informed consent to participate in the re-
search. Exclusion criteria were patient age <18 or >60 
years and diagnosis of a neurological disorder. The re-
search was carried out within the premises of the Clin-
ical Centre of Vojvodina Polyclinic, at the time when 
patients were receiving their regular therapy with the 
long-acting antipsychotic Risperdal Consta® ( Jans-
sen-Cilag Pharma GmbH, Vienna, Austria). This 
study included patients that were treated at a psychiat-
ric ward and were receiving atypical antipsychotic 
therapy. One of the reasons for including only patients 
on this type of therapy was that patients treated with 
atypical antipsychotics had fewer side effects than 
those treated with typical antipsychotics, which have 
the advantage of reducing depressive symptoms5,20,21. 
In addition, we thought that patients (owing to the 
fact that atypical antipsychotics cause much less cog-
nitive impairment compared to typical antipsychotics) 
would be able to demonstrate more appropriate levels 
of understanding the requirements of the researcher 
and to actively participate in the research.
The present study was approved by the Ethics Com-
mittee of the Clinical Center of Vojvodina. All respon-
dents were offered general information regarding the 
type and purpose of the study, and they voluntarily 
agreed to parcipate in it by signing an informed consent. 
All procedures performed in studies involving human 
participants were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and with the 1964 Helsinki Declaration and its 
later amendments or comparable ethical standards.
Instruments
Two instruments were used, i.e. the Positive and 
Negative Syndrome Scale (PANSS)22,23 and Calgary 
Depression Scale for Schizophrenia (CDSS)18,24.
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The PANSS comprises three subscales, Positive, 
Negative and General Psychopathology subscales. 
Each subscale was scored separately, based on the re-
searcher’s appraisal obtained during an interview, ac-
cording to the PANSS Evaluation Manual for assess-
ing each parameter. The Positive and Negative Sub-
scales comprise 7 items each, rated by use of the sever-
ity levels from 1 to 7. Additionally, total score for each 
of these subscales can range from 7 to 49. The General 
Psychopathology subscale consists of 16 items, with a 
total score ranging from 16 to 112.
A composite score is derived by subtracting Total 
Negative from Total Positive score. The composite 
score can range from -42 to +42, and based on this 
predictive value, the presence of negative symptoms is 
estimated in relation to positive symptoms. The Com-
posite Scale shows the predominance of positive or 
negative symptoms and its direct score ranges from 
-42 to +42 and is a difference score for Positive minus 
Negative direct scores. Therefore, all the scores greater 
than +11 indicate the predominance of positive symp-
toms, whereas the scores lower than -15 indicate the 
predominance of negative symptoms (5th and 95th per-
centile). The symptoms closer to zero-score indicate a 
combined type, i.e. means of symptoms are evenly dis-
tributed between the two types.
In particular, composite score obtained by subtract-
ing the Total Negative score from the Total Positive 
score stands out, showing the presence and severity of 
negative in relation to positive symptoms. Comparing 
some subscale scores provides an insight into the basic 
structure of schizophrenia subtypes.
The CDSS was specifically designed for patients 
with schizophrenia and it is considered as one of the 
most reliable criteria for predicting depressive episodes 
in these patients. Compared to other scales, the CDSS 
is most effective in differentiating depressive symptoms 
from negative symptoms in schizophrenia; accordingly, 
the use of this scale decreases the risk of not being rec-
ognized as a depressive disorder or misdiagosed. The 
CDSS consists of a nine-item structured interview scale 
in which each of eight items is scored based on the pa-
tient’s direct responses to structured interviewing, ex-
cept for the last item which is rated by the researcher, 
based on observations of the entire interview. Items are 
based on the current, i.e. the last two-week time. Each 
item can be scored on a scale ranging from 0 to 3, with 
the total score ranging from 0 to 27.
The questionnaire was designed for the purpose of 
this study covering socio-demographic factors associ-
ated with an increased risk of depression among these 
patients. Respondents answered questions about the 
place of residence, educational level and occupational 
status, socio-economic status, marital status, parenting, 
hospitalization, and previous history of hetero-aggres-
sive behavior. All respondents were asked whether 
they felt lonely, whether they believed the provision of 
support provided by their families and society was ad-
equate, and whether they felt socially isolated. More-
over, patients were asked specific questions about ther-
apy, such as how long they had been receiving the 
long-acting antipsychotic Risperdal Consta®, what 
psychopharmaceuticals other than this one they had 
used, how regularly they followed their therapy and 
how long they were in remission, and questions about 
the presence of psychiatric heredity and family history 
of suicide.
Statistical analysis
Data were analyzed using SPSS 21 statistical soft-
ware. The measures of descriptive statistics (frequen-
cies, percentages, mean values, measures of variability) 
were applied. The Shapiro-Wilk test was used to assess 
normality of data distribution. The significance of 
 differences was determined by nonparametric tests 
(χ2-test and Mann-Whitney U test), and multiple re-
gression analysis was applied to check and analyze the 
possible relationship between variables. The level of 
statistical significance was set at p<0.05.
Results
The presence of clinical depression symptoms was 
examined using the CDSS. Furthermore, analysis of 
the instrument used to predict a depressive episode 
among patients in terms of sensitivity and specificity 
shows that the presence of a depressive episode can be 
assumed in all respondents with CDSS score greater 
than 6, with 82% specificity and 85% sensitivity. Of the 
76 patients examined in this study, 22 (29%) patients 
had scores greater than 6, thus indicating the presence 
of depressive symptoms. All respondents were asked 
whether they had ever thought of taking their lives and 
whether they had really attempted it. In the group of 
patients who had the CDSS score above 6 and who 
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were defined as depressed, 30% of them said they had 
suicidal thoughts and plans for suicide, but then they 
did not implement the plan, while 20% of these pa-
tients had a previous suicide attempt. In the group of 
respondents without depressive symptomatology, 10% 
said they used to think of taking their lives, while 5% 
of these patients had attempted suicide.
The presence of positive and negative symptoms of 
schizophrenia was assessed using the PANSS. Among 
the 76 respondents examined in this study, four re-
ceived a composite score of less than -15, i.e. domi-
nance of negative symptoms was recorded. In the re-
maining 72 respondents, the composite score ranged 
between -15 and +10, yielding a similar prevalence of 
positive and negative symptoms in these patients. 
None of the patients examined had a composite score 
greater than +10.
The mean score on the general psychopathology 
subscale was 29.4 (SD=0.89). In the group of 72 re-
spondents, on the basis of composite score, the pres-
ence of positive and negative symptoms was found to 
be approximately evenly represented, with the mean 
score on the general psychopathology subscale of 
28.91. In the remaining four respondents, i.e. in the 
group of respondents with predominance of negative 
symptoms, the mean score was 34.
In four patients, the composite scores on the 
PANSS indicated predominance of negative symp-
toms, whereas one of these four patients was also 
in the group of patients with a score greater than 6 on 
the CDSS. The mean score on the PANSS gene- 
ral psychopathology subscale in patients who had 
CDSS scores greater than 6 was 35.23, whereas the 
mean score for the remaining patients was 26.63. 
The general psychopathology score was greater in 
those patients whose CDSS scores were greater than 
6, and this difference was statistically significant 
(U=4.91; p=0.00). A statistically significant difference 
was also found on the PANS negative scale (U=3.64; 
p=0.00).



















Place of residence Urban area 17 (85.00) 47 (90.38) χ²=0.42
p=0.51Rural area 3 (15.00) 5 (9.62)






p=0.29Higher education 5 (25.00) 3 (5.77)
Academic education 3 (15.00) 19 (36.54)
Employment
status
Employed 8 (40.00) 32 (61.54)
χ²=3.20
p=0.20Unemployed 4 (20.00) 9 (17.31)
Retired 8 (40.00) 11 (21.15)
Socio-economic 
status
Low 4 (20.00) 34 (65.38)
χ²=18.40
p=0.00Middle 16 (80.00) 13 (25.00)
High 0 5 (9.62)
Marital status Single 12 (60.00) 40 (76.92)
χ²=17.44
p=0.00Married 2 (10.00) 12 (23.07)
Divorced 6 (30.00) 0 
Parenting Accomplished 2 (10.00) 12 (23.08) χ²=1.57
p=0.20Unaccomplished 18 (90.00) 40 (76.92)
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Following further data analysis, four respondents 
with a predominance of negative symtomatology on 
the PANSS (score lower than -15 in the composite 
PANSS score) were excluded from the sample. This 
ensured the risk factors to be analyzed only in patients 
with depressive symptomatology while avoiding over-
lap with negative symtoms. The group with depressive 
symptomatology comprised 20 patients, while the 
group without depressive symptomatology comprised 
52 patients. Table 1 shows distribution of the general 
sociodemographic data in both study groups.
There was a statistically significant difference ac-
cording to gender structure between the groups. In the 
first group, respondents with depressive symptoms 
were slightly younger than those in the second group, 
but the difference was not significant. According to 
the place of residence, there was no significant differ-
ence between the two groups. In both groups, respon-
dents came predominantly from urban areas. Since the 
most frequent level of education was secondary educa-
tion, it is not surprising that the number of respon-
dents who completed secondary school was highest. In 
both groups, most of the respondents were unem-
ployed. A statistically significant difference was ob-
served between the two groups with respect to socio-
economic status, which was assessed lower in the first 
group compared to the second group, who mostly as-
sessed it as average. In both groups, the respondents 
were mostly single, yet with a significant between-
group difference. The difference was not expressed in 
terms of parenting.
Analyzing other factors for the presence of depres-
sion in people with schizophrenia (Table 2), we found 
a statistically significant difference between the groups 
according to the feeling of loneliness, absence of fam-
ily and social support, social isolation, as well as ac-











Yes 18 (90.00) 13 (25.00) χ²=24.89
p=0.00No 2 (10.00) 39 (75.00)
Family support
Present 14 (70.00) 46 (88.46) χ²=8.62
p=0.01Absent 6 (30.00)  6 (11.54)
Social support
Present 5 (25.00) 34 (65.38) χ²=18.63
p=0.00Absent 15 (75.00)  18 (34.62)
Social isolation
Present 16 (80.00) 17 (32.69) χ²=13.02
p=0.00Absent 4 (20.00) 35 (67.31)
Family history of mental 
disorders
Present 9 (45.00) 17 (32.69) χ²=0.94
p=0.33Absent 14 (70.00) 35 (67.31)
Suicide in family
Present 2 (10.00) 11 (21.15) χ²=1.21
p=0.57Absent 18 (90.00) 41 (78.85)
Previous hetero-aggressive 
behavior
Present 15 (75.00) 27 (51.92) χ²=3.16
p=0.07Absent 5 (25,00) 25 (48.08)
Compliance with 
psychopharmacotherapy
Good 11 (55,00) 47 (90.38) χ²=11.54
p=0.00Poor 9 (45.00)  5 (9.62)
Number of hospitalizations 5.48 (SD=4.82) 3.23 (SD=3.31) U=2.35p=0.02
Duration of remission
>1 year 8 (40.00) 7 (13.46) χ²=6.16
p=0.01<1 year 12 (60.00) 45 (86.54)
Mean time elapsed
from last hospitalization (yrs) 1.98 (SD=2.31) 5.30 (SD=5.37)
U=3.40
p=0.02
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cording to the duration of therapy, number of psycho-
pharmaceuticals, compliance of psychopharmacother-
apy, number of hospitalizations, time elapsed from 
previous hospitalization, and duration of remission.
Respondents were found to have a strong family 
support, but in those with depressed symptoms, social 
isolation was more pronounced with a higher inci-
dence of hetero-aggressive behavior. Also, these indi-
viduals had worse psychopharmacotherapy complica-
tions, there were fewer of those with remissions for 
more than a year, and a shorter period of time had 
elapsed from the last hospitalization. In addition, they 
had been treated with Risperdal Consta® for a shorter 
time and in combination of more other psychophar-
maceuticals. The mean duration of therapy with Risp-
erdal Consta® was 3.42 years (SD=4.17) in the group 
of respondents with depressive symptomatology and 
5.54 years (SD=3.83) in the control group (U=3.20; 
p=0.01). The mean number of psychopharmaceuticals 
was 3.45 (SD=1.27) in the group of respondents with 
depressive symptomatology and 2.21 (SD=1.51) in the 
control group (U=2.80; p=0.02). Compared to the 
group of antipsychotics, the group of benzodiazepines 
was more commonly used.
Multinominal logistic regression used depression 
(CDSS) as a dependent variable to estimate the con-
tribution of each independent variable that had a sta-
tistical significance greater than 0.05. The variables 
that were singled out as predictors are shown in Table 
3. The above results show that all the study variables 
associated with depressive symptomatology in the pre-
vious model had a statistically significant predictive 
value, with particular significance observed in compli-
ace with psychopharmacotherapy, previous remission 
duration, social support, and loneliness.
Discussion
Depression in schizophrenia can be interpreted in 
a number of ways in relation to whether it is under-
stood as an integral part of the schizophrenic process 
itself15 or as a consequence of a psychological reaction 
to the development of a schizophrenic disorder25. 
Since the genesis of schizophrenia is considered to be 
multifactorial, the influence of various factors, whether 
environmental or individual, can contribute in a per-
son who has predisposition towards depression to 
 develop symptoms of depression3,7,25,26. Depressive 
moods, anxiety, social withdrawal and emotional de-
tachment often occur in schizophrenia, although they 
are not necessarily unique to schizophrenia27. Given 
that negative symptoms in schizophrenia partially 
overlap with the symptoms of depression, it makes it 
difficult to distinguish between mood symptoms and 
negative symptoms in schizophrenia28.
These symptoms can also be difficult to distinguish 
due to the fact that negative symptomatology can lead 
to the impoverished intrapsychic functioning, so these 
people do not only have difficulties in getting to the root 
cause of a problem, but also in clearly describing them. 







B SE Beta Lower bound
Upper 
bound
Age (yrs) -0.13 0.03 -0.25 -3.34 0.01 -0.21 -0.09
Marital status 1.67 0.56 0.22 2.98 0.04 0.99 3.00
Socioeconomic status 1.58 0.53 0.21 2.94 0.05 0.50 2.47
Loneliness -5.78 0.89 -0.60 -6.43 0.00 -3.46 -0.99
Duration of Risperdal Consta® treatment -0.25 0.08 -0.21 -2.97 0.04 -0.59 -0.30
Psychopharmacotherapy 3.63 0.99 0.30 3.65 0.00 1.75 5.34
Family support 1.08 0.53 0.15 2.01 0.04 0.48 2.60
Social support 2.16 0.44 0.43 4.89 0.00 1.90 3.21
Previous remisssion duration 3.60 0.99 0.31 3.60 0.01 2.35 6.04
SE = standard error; Sig. = significance
B. Golubović et al. Depression in patients with schizophrenia
Acta Clin Croat, Vol. 59, No. 4, 2020 611
Therefore, on the one hand, symptoms have been simi-
larly reported by patients as either one or the other, in-
cluding negative symptoms the manifestation of which 
is often similar to the symptoms of depression.
In this study, depression in schizophrenia was 
clearly objectified using the Calgary scale designed for 
assessment of depression in schizophrenia, whereas 
negative symptoms were estimated using the PANSS. 
The mean PANSS score on the negative scale was 
 significantly higher in patients with depression in 
schizophrenia compared to the control group, as 
 confirmed by previous studies29,30. Negative symptoms 
lead to reduction of adaptive coping skills and poor 
social functioning. They will determine the person’s 
definite level of functioning, the level of autonomous 
functioning and social functioning, employment status 
and family relations.
In this research, gender, socioeconomic status and 
marital status were identified as important socio-demo-
graphic factors. The results obtained are consistent with 
previous studies, showing that gender, coexistence and 
social security are associated with depression7,31,32. Al-
though the reasons for expressing gender differences in 
schizophrenia are still insufficiently clear, suggesting 
that males have more severe clinical features, in addition 
to more frequent negative symptoms33. In the study by 
Rocca et al.32, men predominated among those diag-
nosed with severe clinical depression features.
Socioeconomic status has been found to be a signifi-
cant factor in the development of depression in previous 
studies7,31,34, as also confirmed in this study. Although 
the highest prevalence of symptoms of depression was 
among respondents who had completed secondary 
school, they were mostly unemployed or retired with 
generally lower incomes, and probably meeting work-
related demands due to the nature of their disease or 
doing jobs to make extra money. It should be kept in 
mind that a complete clinical picture reflecting the ill-
ness can be mainly obtained in adolescence, that is, in 
the years that follow the end of secondary school and 
beyond. Thus, the onset of illness can affect a person’s 
capacity to function at work, lowering the level of work 
and consequently causing unemployment.
Consequently, disease related unemployment and 
low income in turn lead to dependency on family and 
social support to meet basic socioeconomic needs. This 
can be seen in reduced quality of life, difficulties in so-
cial integration and participation, and patient marital 
status. Taking into account the early onset of disease33, 
it is not surprising that the majority of respondents 
were unmarried. The number of divorces was also 
higher in the group of respondents with depression, 
and the divorce itself could be one of the factors for the 
emergence of depression due to the lack of support 
from the spouse. A disturbed partner relationship, or 
loneliness arising from divorce or not getting into 
marriage are important factors that lead to depres-
sion35,36. The results in first-time hospitalized patients 
in our study were opposite to those reported by Bot-
tlender et al.30. Their study was conducted in elderly 
patients, meaning that a larger proportion were mar-
ried, thus emphasizing loneliness to a lesser degree. 
Bearing in mind long-standing illness of our respon-
dents and that they were not hospitalized for the first 
time, these types of data would point out the impor-
tance of illness duration and number of previous hos-
pitalizations for the occurrence of depression.
In addition to poor socioeconomic conditions, oth-
er study factors related to social functioning of these 
individuals and the environment in which they reside 
(loneliness, environmental support, social support, so-
cial isolation) show that people with depressive symp-
toms in schizophrenia are more often lonely and so-
cially isolated, with poor support from the environ-
ment and family. Loneliness was significantly more 
common in the group of patients with depression than 
in the control group. This result was expected and con-
sistent with the results of previous studies suggesting 
that loneliness is common in these people as a result of 
social isolation and lack of support from the family 
and environment32,33,35,37. Loneliness is in itself a risk 
factor for the development of depression and suicidal 
ideation and attempts10,14,37, reducing self-esteem and 
increasing social anxiety. A possible explanation has 
been found in several segments that are not adequate 
and/or present. Namely, on the one hand, cognitive 
deficits that arise and possible insight into their condi-
tion reduce the ability to adapt to the newly arisen so-
cial relationships, and on the other hand, there is a 
strong social stigma of those affected by the disease. 
These all contribute to autostigmatization and conse-
quent isolation and loneliness.
Inadequate family and social support revealed in 
this study also coincides with other studies on numer-
ous challenges faced by the families, such as difficulty 
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of accepting a situation in which a family member is 
providing medical and social needs of this person, care 
and uncertain unpredictable future, often accompa-
nied by feelings of concern and guilt35,38. In addition, 
the phenomena of stigmatization39,40 and ‘burnout’ of 
family members make these patients feel deprived of 
family and social support and report a number of 
problems in the interpersonal domain. Results of nu-
meorus studies have shown the signifficant effect of 
social and family support on better social functioning 
in patients with schizophrenia41,42.
The group of respondents with schizophrenia and 
depression had higher PANSS general psychopathol-
ogy scores, which was confirmed by the results of the 
PANSS negative subscale showing the presence of 
negative symptoms, complications from poor psycho-
pharmacotherapy compliance, greater number of hos-
pitalizations, and shorter period of remission in rela-
tion to the severity of clinical manifestations. The re-
sults of this study are consistent with the results of 
other studies28,32,43-45, confirmed by poor adherence to 
psychopharmacotherapy that is common and associ-
ated with negative outcomes in these patients. It is es-
timated that the recommended drug administration 
rate is about 50%43,44. Poor compliance can increase the 
risk of relapse, worsening of symptoms and re-hospi-
talizations. Furthermore, frequent relapses of the dis-
ease with frequent rehospitalizations are risk factors 
for the incidence of suicide risk in schizophrenia, espe-
cially in later course of the disease10,14,37. Risk factors 
that are positively correlated with social functioning of 
a person, such as social isolation, loneliness and envi-
ronmental support are also contributing to poor psy-
chopharmacotherapy compliance, increased number of 
hospitalizations and shorter remission periods.
Using the multiple logistic regression model, statis-
tically significant predictors of depression in patients 
diagnosed with schizophrenia are prior length of re-
mission, compliance with psychopharmacotherapy, so-
cial support, marital status, and socioeconomic status.
Compliance with psychopharmacotherapy ensures 
good treatment outcome and consequently good con-
trol of schizophrenic disorder leading to longer remis-
sion periods. More stability in the primary disease 
gives the patient further confidence in terms of con-
trolling the disease. Consequently, patients grow in 
confidence and have greater self-confidence when 
functioning in general and hence in social interactions. 
Richer social life results in greater self-confidence, as 
well as better and more stable mood.
Negative warning signs indicate that our respon-
dents are lonely, younger people with short-term treat-
ment. If the results are viewed in a broader context, the 
absence of social support that affects almost all func-
tioning domains of those affected by the illness, i.e. per-
sonal, family and professional, play a very important 
role in prediction of depression in schizophrenia. This 
points to the importance of greater community en-
gagement in improving the living conditions, work en-
vironment, and everyday functioning of these people.
Bearing in mind that depression may be caused by 
the primary disease, i.e. schizophrenia, but also reac-
tively triggered, after further insight derived from the 
findings of our study, the lack of patient functional 
self-assessment can be added as a potential limitation 
to findings. This study aimed to provide further insight 
into the self report. Furthermore, a larger number of 
respondents would contribute to greater accuracy of 
data, in addition to including respondents from vari-
ous institutions. Since the study included only subjects 
receiving atypical antipsychotics, it would also be im-
portant to include patients receiving typical antipsy-
chotic therapy.
Conclusion
It is estimated that depression occurs in one-third 
of respondents with schizophrenia. It is often accom-
panied by the lack of social and family support and 
may have an impact on all aspects of the individual’s 
life and directly affect them. Namely, the number of 
social relationships is reduced, the chance of making 
new acquaintances, emotional bonding, and the chance 
of finding a job is decreased. The disease course contin-
ues to worsen with short periods of remission directly 
related to medication adherence, i.e. taking medica-
tions as prescribed. Since the presence of these factors 
is associated with depression in schizophrenia, their 
early detection in clinical practice is vital to ensure 
timely prevention of the development of depressive 
symptomatology.
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Sažetak
ČIMBENICI POVEZANI S DEPRESIJOM U BOLESNIKA SA SHIZOFRENIJOM
B. Golubović, Z. Gajić, O. Ivetić, J. Milatović, P. Vuleković, Đ. Đilvesi, S. Golubović, F. Vrban, A. Subašić i L. Rasulić
Cilj ovoga rada bio je analizirati čimbenike rizika prisutne u shizofrenih bolesnika s depresivnom simptomatologijom. 
Uzorak se sastojao od 76 ispitanika s dijagnozom shizofrenije. U studiji smo koristili Ljestvicu za procjenu pozitivnog i 
 negativnog sindroma kod shizofrenije (PANSS) i Kalgarijsku ljestvicu depresije. Procjenjuje se da je učestalost depresije 30%. 
Prosječni rezultati na negativnoj podljestvici PANSS-a bili su značajno veći u bolesnika sa shizofrenijom i depresijom u 
 usporedbi s kontrolnom skupinom (U=3,64, p=0,00), kao i na općoj psihopatološkoj ljestvici (U=4,91, p=0,00). Socio-demo-
grafski čimbenici identificirani su kao važni čimbenici (p<0,05). Osobni i okolišni čimbenici, kao što su usamljenost, nepo-
sredna društvena okolina, socijalna potpora i izolacija statistički se značajno razlikuju među skupinama (p<0,05). Postoji 
korelacija između slabe usklađenosti s psihofarmakoterapijom, povećanog broja hospitalizacija, kao i kraćeg razdoblja remi-
sije s težinom kliničke slike (p<0,05). Budući da je prisutnost ovih čimbenika povezana s depresijom u shizofreniji, njihovo 
rano otkrivanje u kliničkoj praksi je od vitalnog značenja za pravodobno sprječavanje razvoja depresivne simptomatologije.
Ključne riječi: Shizofrenija; Depresija; Sociodemografski čimbenici
